Literature DB >> 34914034

Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments.

Nicole Gusset1,2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34914034     DOI： 10.1007/s40273-021-01122-6

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  10 in total

1.  Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.

Authors:  Katy Benjamin; Margaret K Vernon; Donald L Patrick; Eleanor Perfetto; Sandra Nestler-Parr; Laurie Burke
Journal:  Value Health       Date:  2017 Jul - Aug       Impact factor: 5.725

2.  Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper.

Authors:  Ann N V Single; Karen M Facey; Heidi Livingstone; Aline Silveira Silva
Journal:  Int J Technol Assess Health Care       Date:  2019-07-24       Impact factor: 2.188

3.  Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy.

Authors:  Nicole Gusset; Caroline Stalens; Eva Stumpe; Lori Klouvi; Alexandre Mejat; Marie-Christine Ouillade; Mencía de Lemus
Journal:  Neuromuscul Disord       Date:  2021-02-04       Impact factor: 4.296

4.  Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

Authors:  Sandra Nestler-Parr; Daria Korchagina; Mondher Toumi; Chris L Pashos; Christopher Blanchette; Elizabeth Molsen; Thomas Morel; Steven Simoens; Zoltán Kaló; Ruediger Gatermann; William Redekop
Journal:  Value Health       Date:  2018-04-11       Impact factor: 5.725

Review 5.  Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment.

Authors:  Katarzyna Pierzchlewicz; Izabela Kępa; Jacek Podogrodzki; Katarzyna Kotulska
Journal:  Child Neurol Open       Date:  2021-04-27

6.  A qualitative study of perceptions of meaningful change in spinal muscular atrophy.

Authors:  Sarah McGraw; Ying Qian; Jeff Henne; Jill Jarecki; Kenneth Hobby; Wei-Shi Yeh
Journal:  BMC Neurol       Date:  2017-04-04       Impact factor: 2.474

7.  Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.

Authors:  Siu Hing Lo; Claire Lawrence; Yasmina Martí; Andreia Café; Andrew J Lloyd
Journal:  Pharmacoeconomics       Date:  2021-12-13       Impact factor: 4.981

8.  Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.

Authors:  C Simone Sutherland; Pollyanna Hudson; Stephen Mitchell; Noman Paracha
Journal:  Pharmacoeconomics       Date:  2021-12-15       Impact factor: 4.981

9.  Design and Conduct Considerations for First-in-Human Trials.

Authors:  Jie Shen; Brandon Swift; Richard Mamelok; Samuel Pine; John Sinclair; Mayssa Attar
Journal:  Clin Transl Sci       Date:  2018-08-24       Impact factor: 4.689

10.  Value Assessment Frameworks in the United States: A Call for Patient Engagement.

Authors:  Vakaramoko Diaby; Askal A Ali; Alberto J Montero
Journal:  Pharmacoecon Open       Date:  2019-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.